The opposing actions of target of rapamycin and AMP-activated protein kinase in cell growth control

Sravanth K Hindupur1, Asier González1, Michael N Hall1

  • 1Biozentrum, University of Basel, CH4056 Basel, Switzerland.

Insights

The target of rapamycin (TOR) and AMP-activated protein kinase (AMPK) are key regulators of cell growth. This review highlights their opposing roles in balancing anabolic and catabolic processes for cellular homeostasis.

Area of Science:

  • Cellular biology
  • Molecular biology
  • Biochemistry

Background:

  • Cell growth requires a balance between anabolic and catabolic processes.
  • The target of rapamycin (TOR) pathway promotes growth, responding to nutrients and growth factors.
  • AMP-activated protein kinase (AMPK) inhibits growth during energy stress.

Purpose of the Study:

  • To review the critical roles of TOR and AMPK in cell growth regulation.
  • To emphasize the mutually antagonistic signaling between TOR and AMPK.

Main Methods:

  • Literature review of conserved eukaryotic signaling pathways.
  • Analysis of molecular mechanisms governing cell growth.
  • Integration of data on nutrient and energy stress responses.

Main Results:

  • TOR and AMPK are conserved throughout eukaryotic evolution.
  • TOR signaling promotes anabolic processes, driving cell growth.
  • AMPK signaling suppresses anabolic processes, conserving energy.

Conclusions:

  • TOR and AMPK act antagonistically to control cell growth.
  • This balance is fundamental for maintaining cellular homeostasis.
  • Understanding these pathways is crucial for metabolic and growth research.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K